Should my baby receive the new RSV monoclonal antibody vaccine?

RSV (respiratory syncitial virus) is one of the leading causes of lower respiratory tract infections in infants. It can lead to severe complications like bronchiolitis or pneumonia.  Monoclonal antibodies provide immediate immunity by giving your baby pre-made antibodies, offering protection without requiring the baby's immune system to produce its own response. 

Monoclonal antibody vaccines are specifically designed to neutralize RSV and have shown in clinical trials to significantly reduce hospitalizations and severe RSV-related illnesses. 

These vaccines provide protective effects for about 5 months which covers the peak of RSV season, fall and winter, when babies are most at risk of exposure. 

Infants, especially those born prematurely or with underlying health conditions are at higher risk of severe RSV. The vaccine is of particular benefit to these vulnerable groups. 

Protecting your baby also helps reduce RSV transmission within the community, which then benefits other children and adults, particularly those with weaker immune systems. 

Monoclonal antibody vaccines are generally well tolerated with side effects usually limited to mild reactions like soreness at the injection site. 

Talk to your pediatrician for more information.